medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2007, Número 4

<< Anterior Siguiente >>

Ann Hepatol 2007; 6 (4)


Dipeptidyl peptidase IV (DDP IV) in NASH patients

Balaban YH, Korkusuz P, Simsek H, Gokcan H, Gedikoglu G, Pinar A, Hascelik G, Asan E, Hamaloglu E, Tatar G

Idioma: Ingles.
Referencias bibliográficas: 35
Paginas: 242-250
Archivo PDF: 296.65 Kb.


FRAGMENTO

Sin resumen


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Neuschwander-Tetri B, Caldwell SH. Nonalcoholic steatohepatitis: Summary of an AASLD single topic conference. Hepatology 2003; 37: 1202-1219.

  2. Cheng D. Prevalence, predisposition and prevention of type II diabetes. Nutr Metab (Lond) 2005; 2: 29.

  3. Medina J, Fernandez-Salazar LI, Garcia-Buey L, Moreno-Otero R. Approach to the pathogenesis and treatment of nonalcoholic steatohepatitis. Diabetes Care 2004; 27: 2057-2066.

  4. Marchesini G, Brizi M, Bianchi G, Tomessetti S, Bugianesi E, Lenzi M, McCullough AJ, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001; 50: 1844-1850.

  5. Ong JP, Younossi ZM. Is hepatocellular carcinoma part of the natural history of nonalcoholic steatohepatitis. Gastroenterology 2002; 123: 373-378.

  6. Lambeir AM, Durinx C, Scharpe S, De Meester I. Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci 2003; 40: 209-294.

  7. McCaughan GW, Gorrell MD, Bishop GA, Abbott CA, Shackel NA, McGuinness PH, Levy MT, et al. Molecular pathogenesis of liver disease: an approach to hepatic inflamation, cirrhosis and liver transplant tolerence. Immunol Rev 2000; 174: 172-191.

  8. Ogata S, Misými Y, Ikehara Y. Primary structure of rat liver dipeptidyl peptidase IV deduced from its cDNA and identification of the NH2-terminal signal sequence as the membrane-anchoring domain. J Biol Chem 1989; 264: 3596-3601.

  9. Ahren B, Ladin-Olsson M, Jansson PA, Svensson M, Holmes D, Schweizer A. Inhibition of dipeptidyl peptidase-4 glycemia, sustains insuline levels, and reduces glucagone levels in type 2 diabetes. J Clin Endocrinol Metab 2004; 89: 2078-2084.

  10. Kendall DM, Kim D, Maggs D. Incretin mimetics and dipeptidyl peptidase-IV inhibitors: a review of emerging therapies for type 2 diabetes. Diabetes Technol Ther 2006; 8: 385-396.

  11. Deacon CF. Therapeutic strategies based on glucagon-like peptide 1. Diabetes 2004; 53: 2181-2189.

  12. Pospisilik JA, Stafford SG, Demuth HU, McIntosh CHS, Pederson RA. Long-term treatment with dipeptidyl peptidase IV infibitor improves hepatic and periphereal insulin sensitivity in the VDF zucker rat. A euglycemic-hyperinsulinemic clamp study. Diabetes 2002; 51: 2677-2683.

  13. Reimer MK, Holst JJ, Ahren B. Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islent function in mice. Eur J Endocrinol 2002; 51: 2677-2683.

  14. Takasaki K, Nakajima T, Ueno K, Nomoto Y, Higo K. Effects of combination treatment with dipeptidyl peptidase IV inhibitor and sulfonylurea on glucose level in rats. J Pharmacol 2004; 95: 291-293.

  15. Yasuda N, Nagakura T, Yamazaki K, Inoue T, Tanaka I. Improvement of high fat-diet-induced insulin resistance in dipeptidyl peptidase IV-deficient Fischer rats. Life Sci 2002; 71: 227-238.

  16. Barnett A. DPP-4 inhibitors and their potential role in the management of type 2 diabetes. Int J Clin Pract 2006; 60: 1454-1470.

  17. Nagatsu T, Hino M, Fuyamada H, Hayakawa T, Sakakibara S, Nakagawa Y, Takemoto T. New chromogenic substrates for x-prolyl dipeptidyl-aminopeptidase. Anal Biochem 1976; 74: 466-476.

  18. Brunt EM, Janney CJ, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Non-alcoholic steatohepatitis: a proposal for grading and staging the histologic lesions. Am J Gastroenterol 1999; 94: 2467-2474.

  19. Tokgozoglu L, Can I, Korkusuz P, Asan E, Ozer N, Deminci M. Correlation of tissue selectin expression and hemodynamic parameters in rheumatic mitral valve disease. J Heart Valve Dis 2006; 15: 671-678.

  20. Portincasa P, Grattagliano I, Palmieri VO, Palasciano G. Current pharmacological treatment of nonalcoholic fatty liver. Curr Med Chem 2006; 13: 2889-2990.

  21. Gines S, Mariño M, Mallol J, Canela EI, Morimoto C, Callebaut C, Hovanessian A, et al. Regulation of epithelial and lymphocyte cell adhesion by adenosine deaminase-CD26 interaction. Biochem J 2002; 361: 203-209.

  22. Pacheco R, Martinez-Navio JM, Lejeune M, Climent N, Oliva H, Gatell JM, Gallart T, et al. CD26 adenosine deaminase, and adenosine receptors mediate costimulatory signals in the immunological synapse. PNAS 2005; 102: 9583-9588.

  23. Boonacker EP, Wierenga EA, Smits HH, Van Noorden CJF. CD26/DPPIV signal transduction function, but not proteolytic activity, is directlyrelated to its expression level on human Th1 and Th2 cell lines as detected with living cell cytochemistry. J Histochem Cytochem 2002; 50: 1169-1177.

  24. Kürktschiev D, Subat S, Adler D, Schentke KU. Immunomodulating effect of ursodeoxycholic acid therapy in patients with primary biliary cirrhosis. J Hepatology 1993; 18: 373-377.

  25. Czaja MJ. Liver injury in the setting of steatosis: crosstalk between adipokine and cytokine. Hepatology 2004; 40: 19-22.

  26. Dang NH, Torimoto Y, Schlossman SF, Morimoto C. Human CD4 helper T cell activation: functional involvement of two distinct collagen receptors, 1F7 and VLA integrin family. J Exp Med 1990; 172: 649-652.

  27. Gali A, Crabb DW, Ceni E, Salzano R, Mello T, Svegliati-Baroni G, et al. Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro. Gastroenterology 2002; 122: 1924-1940.

  28. Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, et al. A placebo-controlled trial of pioglitazone in subjects with non-alcoholic steatohepatitis. N Engl J Med 2006; 355: 2297-2307.

  29. McCaughan GW, Wickson JE, Creswick PF, Gorrell MD. Identification of the bile canalicular cell surface molecule GP110 as the ectopeptidase dipeptidyl peptidase IV: an analysis of tissue distribution, purification and N-terminal amino acid sequence. Hepatology 1990; 11: 534-544.

  30. Matsumoto Y, Bishop GA, McCaughan GW. Altered zonal expression of CD26 antigen (dipeptidyl peptidase IV) in human cirrhotic liver. Hepatology 1992; 15: 1048-1053.

  31. Perner F, Gyuris T, Rakoczy G, Salvary E, Gorog D, Szalay F, et al. Dipeptidyl peptidase activity of CD26 in serum and urine as a marker of cholestasis: Experimental and clinical evidence. J Lab Clin Med 1999; 134: 56-67.

  32. Maes M, Lin A, Bonaccorso S, Vandoolaeghe E, Song C, Goossens F, et al. Lower activity of serum peptidases in abstinent alcohol-dependent patients. Alcohol 1999; 17: 1-6.

  33. Fierneisz G, Lakatos PL, Hungarian Viral Hepatitis Study Group, and Szalay F. Serum dipeptidyl peptidase IV (DPP IV, CD26) activity in chronic hepatitis C. Scand J Gastroenterol 2001; 8: 877-880.

  34. Durinx C, Neels H, Van der Auwera JC, Naelaerts K, Scharpe S, De Meester I. Reference values for plasma dipeptidyl-peptidase IV activity and their association with other laboratory parameters. Clin Chem Lab Med 2001; 39: 155–159.

  35. Meneilly GS, Demuth HU, McIntosh CH, Pederson RA. Effect of ageing and diabetes on glucose dependent insulinotropic polypeptide and dipeptidyl peptidase IV responses to oral glucose. Diabet Med 2000; 17: 346-350.




2020     |     www.medigraphic.com